Tag: CRBN
-
Bristol Myers Squibb’s Zenbexus Cuts Progression or Death Risk by 51% in Phase 3 Trial
Bristol Myers Squibb’s Zenbexus regimen reduced the risk of progression or death by 51% and extended median progression-free survival to 42 months in Phase 3 EXCALIBER-RRMM.